[Atorvastatin in the treatment of high risk patients with ischemic heart disease and dyslipidemia. Safety assessment in the Russian Multicenter Study ATLANTIKA].
V Iu
VIu
Mareev
D054058:Acute Coronary Syndrome / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D000368:Aged; D001219:Aspartate Aminotransferases / Q000378:metabolism; D000069059:Atorvastatin; D057186:Comparative Effectiveness Research; D054796:Drug Dosage Calculations; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D008055:Lipids / Q000097:blood; D008297:Male; D053858:Metabolic Networks and Pathways / Q000187:drug effects; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects; D018570:Risk Assessment; D012426:Russia; D055502:Secondary Prevention; D016896:Treatment Outcome
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011758:Pyrroles; D000069059:Atorvastatin; D001219:Aspartate Aminotransferases